Sodium Phosphate, Monobasic
Active ingredient
- Drug class
- -
- Availability
- See label
- Routes
- Intravenous
- Markets covered
- 1
- Products on record
- 1
Overview
Sodium Phosphate, Monobasic is an active pharmaceutical ingredient. The information below is compiled per regulator from the product labels on record, with direct links to the original documents.
Regulatory status by market
| Market | Regulator | Products | Last revision |
|---|---|---|---|
| CA Canada | Health Canada | 1 | April 10, 2026 |
CACanada· Health Canada
1 product
Uses
AND CLINICAL USE
Intravenous phosphate is indicated in the presence of severe hypophosphatemia, with clinical manifestations of phosphate depletion such as mental derangements, hemolysis and rhabdomyolysis. CONTRAINDICATIONS Phosphate is contraindicated in diseases where high sodium, high phosphate or low calcium may be encountered.
PRECAUTIONS Use with caution in patients with renal impairment, cirrhosis, cardiac failure, and other edematous or sodium retaining states. Use with caution in patients with oliguria or anuria. Plasma-electrolyte concentrations, expecially inorganic phosphate, calcium and sodium, and renal function should be carefully monitored.
Diluted solutions must be infused slowly. ADVERSE REACTIONS Adverse reactions involve the possibility of combined sodium and phosphate intoxication from overdosage. Phosphate intoxication results in a reduction of serum calcium, and the symptoms are those of hypocalcemic tetany.
Sources & citations
- [1]Health Canada (DPD) · 00896187 · revised April 10, 2026
Information on this page is compiled from public regulatory records. Drugvu is not affiliated with any regulator or pharmaceutical manufacturer. This is not medical advice. Always consult a qualified healthcare professional.